Investment Rating - The investment rating for the company is "Recommended" [4][12]. Core Views - The company reported a revenue of 9.19 billion yuan in 2024, a year-on-year increase of 1.4%, but the net profit attributable to shareholders decreased by 15.1% to 590 million yuan due to increased impairment losses [4][7]. - In Q1 2025, the company achieved a revenue of 1.27 billion yuan, a year-on-year decline of 14.3%, while the net profit attributable to shareholders increased by 14.2% to 100 million yuan [4][7]. - The company plans to distribute a cash dividend of 3.2 yuan per 10 shares (including tax) for 2024 [4]. Summary by Sections Financial Performance - In 2024, the company experienced a revenue of 9.19 billion yuan, with a slight decrease in gross margin to 18.1% [7]. - The net profit for 2024 was 590 million yuan, reflecting a significant decline due to impairment losses totaling 430 million yuan [7]. - The company’s revenue for Q1 2025 was 1.27 billion yuan, with a gross margin increase to 20.9% [7]. Business Segments - The decorative materials segment generated 7.4 billion yuan in revenue, a year-on-year increase of 7.99%, with a gross margin of 17.04% [7]. - The custom home segment reported a revenue of 1.72 billion yuan, a decrease of 18.73%, primarily due to challenges in the engineering business [7]. Cash Flow and Financial Health - The net cash flow from operating activities for 2024 was 1.15 billion yuan, down from 1.91 billion yuan in the previous year [8]. - The company’s total assets were 5.92 billion yuan in 2024, with a debt-to-asset ratio of 46.6% [9][10]. Future Projections - The company is projected to achieve net profits of 749 million yuan in 2025, 883 million yuan in 2026, and 957 million yuan in 2027 [8][10]. - The expected P/E ratios for the upcoming years are 12.3 for 2025, 10.4 for 2026, and 9.6 for 2027 [8][10]. Market Position and Strategy - The company is expanding its rural store network significantly, with 1,413 new stores established, bringing the total to 5,522 [7]. - The company is focusing on channel transformation and has strengthened its partnerships with suppliers and distributors [8].

其 他 报 告 2025年04月25日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3297 | 0.03 | 1.19 | | 深证成份指数 | 9878 | -0.58 | -0.54 | | 沪深300指数 | 3784 | -0.07 | 0.59 | | 创业板指数 | 1936 | -0.68 | -0.64 | | 上证国债指数 | 224 | 0.00 | 0.02 | | 上证基金指数 | 6763 | -0.33 | 0.32 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 21910 | -0.74 | 2.30 | | 中国香港国企指数 | 8057 | -0.73 | 1.23 | | 中国台湾加权指数 | 19479 | -0.82 | -0.68 | | 道琼斯指数 | 39607 | ...

Investment Rating - The report assigns a "Buy" rating for Kelun Biotech, marking its first coverage with a target price of 300 HKD [1]. Core Insights - Kelun Biotech is transitioning towards an integrated model of research and sales, with its core product, SKB264 (Lukangshatuo monoclonal antibody), having received approval for two indications in China [6][18]. - The company has a robust pipeline with over 30 products in development, including 11 ADC (Antibody-Drug Conjugate) candidates that are in clinical stages [11][18]. - The partnership with MSD has led to 12 global Phase III studies for SKB264, enhancing its clinical and commercial potential [7][32]. Summary by Sections Major Data - The company operates in the pharmaceutical industry, with a total market capitalization of 63.32 billion CNY and a debt-to-asset ratio of 22.48% [1]. Financial Performance - In 2024, the company reported a revenue of 1.933 billion CNY, a year-on-year increase of 25.5%, while net losses narrowed to 267 million CNY, a 53.5% improvement from the previous year [6][16]. - The gross margin is projected to improve from 49.3% in 2023 to 80.2% by 2027, indicating a positive trend in profitability [5]. Product Pipeline - The core product SKB264 has been approved for treating 3L TNBC and 3L EGFR mutation NSCLC, with additional applications pending for 2L EGFR mutation NSCLC expected to be approved in 2025 [30][29]. - The company has established a strong ADC platform and is actively pursuing global collaborations to maximize the potential of its pipeline [11][18]. Strategic Positioning - Kelun Biotech aims to become a comprehensive pharmaceutical company through innovation, global partnerships, and self-sales capabilities, with a focus on expanding its commercial team and enhancing market access [18][6]. - The management team comprises experienced professionals from both domestic and international pharmaceutical sectors, which is expected to drive the company's long-term growth [14].

证券研究报告 袁喆奇 投资咨询资格编号：S1060520080003 行业评级 【平安证券】 从年报看国有大行经营与资产配置变化 银行行业深度报告 许 淼 投资咨询资格编号： S1060525020001 银行 强于大市（维持） 研究助理 李灵琇 一般从业资格编号： S1060124070021 2025年4月24日 请务必阅读正文后免责条款 投资要点 证券分析师 目录CO N T E N T S 风险分析：资产质量平稳，关注零售风险波动 盈利分析：六大行盈利同比增幅走阔 1.1 整体分析：盈利增速边际改善，农行增速领跑大行 1.2 息差分析：存款付息率同步下行，交行降幅领跑大行 1.3 非息收入：中收延续下行，其他非息贡献抬升 1.4 费用：成本管控力度持续以应对收入增长放缓 3.1 资产质量：整体稳健，关注零售波动 3.2 风险抵御能力：拨备水平相对充足，安全垫充分 分红与战略分析：分红高位稳定，战略突出五篇大文章 盈利分析：盈利边际改善，农行增速领跑大行。24年全年六家国有银行实现净利润同比增长1.8%，增速较前三季度提升1.0pct，农行 净利润同比上行4.7%居同业首位。从营收来看，六家国有行营收同 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting the stock to outperform the market by over 20% within the next six months [13]. Core Insights - The company achieved a revenue of 5.385 billion yuan in 2024, reflecting a year-on-year growth of 2.72%. However, the net profit attributable to shareholders decreased by 12.60% to 407 million yuan, primarily due to a decline in gross margin and increased R&D expenses [3][8]. - The fourth quarter of 2024 showed significant improvement, with revenue reaching 1.690 billion yuan, a year-on-year increase of 23.76%, and a positive net profit from core operations of 48 million yuan [8][9]. - The company is focusing on the edge intelligence sector, particularly in robotics and smart wearable devices, which are expected to be new growth drivers [9]. Summary by Sections Financial Performance - In 2024, the company reported a total revenue of 5.385 billion yuan, with a net profit of 407 million yuan, down from the previous year [3][8]. - The gross margin decreased by 2.66 percentage points compared to the previous year, leading to a reduction in gross profit by approximately 90.63 million yuan [8]. - The company plans to distribute a cash dividend of 0.58 yuan per share, totaling approximately 26.65 million yuan [3]. Revenue and Profit Forecast - Revenue projections for 2025-2027 are estimated at 6.127 billion yuan, 7.202 billion yuan, and 8.579 billion yuan, respectively, with corresponding net profits of 449 million yuan, 540 million yuan, and 657 million yuan [7][10]. - The expected EPS for 2025, 2026, and 2027 are 0.98 yuan, 1.17 yuan, and 1.43 yuan, respectively [10][11]. Strategic Initiatives - The company is advancing its "滴水OS" platform and has established strategic partnerships with various global automotive manufacturers to enhance its smart vehicle offerings [9]. - New product launches in the AI glasses and mixed reality sectors are expected to set industry benchmarks and drive future growth [9]. - The company is expanding its industrial mobile robot business, with new products showcased at industry events [9]. Market Position and Valuation - The company’s P/E ratios for 2025, 2026, and 2027 are projected to be 54.5x, 45.3x, and 37.2x, respectively, indicating a favorable valuation trend [11]. - The company maintains a strong balance sheet with a debt-to-asset ratio of 19.3% and a current ratio of 3.1, reflecting solid financial health [11][12].

Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expected stock performance that will exceed the market by more than 20% within the next six months [14]. Core Insights - The company achieved a revenue of 1.541 billion yuan in Q1 2025, reflecting a year-on-year growth of 10.10%. The net profit attributable to shareholders was 327 million yuan, up 15.83% year-on-year, with a non-recurring net profit of 305 million yuan, increasing by 20.14% [5][6]. - The overall gross margin for Q1 2025 was 42.54%, showing a slight decrease of 0.98 percentage points. However, the net profit margin improved to 21.19%, an increase of 1.05 percentage points, indicating better profit growth compared to revenue growth [6]. - The emerging business segment saw a revenue increase of over 80% year-on-year, contributing significantly to the overall revenue growth, particularly from peptide, small nucleic acid, and ADC businesses [7]. Summary by Sections Financial Performance - Q1 2025 revenue was 1.541 billion yuan, with a gross margin of 42.54% and a net profit margin of 21.19% [5][6]. - The company forecasts net profits of 1.126 billion yuan, 1.378 billion yuan, and 1.740 billion yuan for 2025, 2026, and 2027 respectively [7]. Business Segments - Small molecule revenue remained stable compared to the previous year, with a gross margin of 45.17%. The emerging business segment's revenue exceeded 317 million yuan, continuing its strong performance from Q4 2024 [7]. - The report highlights the potential for growth in small molecule business revenue and margins throughout the year due to ongoing projects and production cycles [7]. Future Projections - The company is expected to see a recovery in global innovative drug development, which will positively impact its business performance [7]. - The report maintains profit forecasts for 2025-2027, projecting a gradual increase in revenue and net profit margins over the years [8][12].

公 司 报 告 医药 2025年04月24日 奥浦迈(688293.SH) 培养基业务迅速发展，CDMO拖累短期业绩 推荐 ( 维持) 股价:41.47元 主要数据 相关研究报告 【平安证券】奥浦迈（688293.SH）*季报点评*补税 影响当期利润，培养基业务势头良好*推荐20241031 证券分析师 倪亦道 投资咨询资格编号 S1060518070001 021-38640502 事项： 公司发布2024年年报，全年实现营收2.97亿元（+22.26%），实现归母净利 润0.21亿元（-61.04%），扣非后归母净利润为658.59万元（-81.03%）。与 业绩快报基本一致。 公司发布分红预案：拟每10股派现2.00元（含税）。 平安观点： | 行业 | 医药 | | --- | --- | | 公司网址 | www.opmbiosciences.com | | 大股东/持股 | 肖志华/24.90% | | 实际控制人 | 肖志华,贺芸芬 | | 总股本(百万股) | 114 | | 流通A股(百万股) | 77 | | 流通B/H股(百万股) | | | 总市值(亿元) | 47 | | 流通A股市 ...

其 他 报 告 2025年04月24日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3296 | -0.10 | 1.19 | | 深证成份指数 | 9936 | 0.67 | -0.54 | | 沪深300指数 | 3787 | 0.08 | 0.59 | | 创业板指数 | 1949 | 1.08 | -0.64 | | 上证国债指数 | 224 | 0.00 | 0.02 | | 上证基金指数 | 6785 | 0.26 | 0.32 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 22073 | 2.37 | 2.30 | | 中国香港国企指数 | 8116 | 2.08 | 1.23 | | 中国台湾加权指数 | 19639 | 4.50 | -0.68 | | 道琼斯指数 | 39607 | 1.07 | ...

Investment Rating - The investment rating for the company is "Recommended" (maintained) with a stock price of 45.18 CNY [1][3]. Core Insights - The company achieved a revenue of 23.343 billion CNY in 2024, representing a year-on-year growth of 18.79%, while the net profit attributable to shareholders was 560 million CNY, a decrease of 14.78% compared to the previous year [3][6]. - In Q1 2025, the company reported a revenue of 4.658 billion CNY, showing a year-on-year increase of 27.74%, but incurred a net loss of 193 million CNY, although this loss was reduced by 35.68% year-on-year [3][6]. - The company plans to distribute a cash dividend of 1 CNY per 10 shares to all shareholders [3]. Revenue and Profitability - The company has shown consistent revenue growth, with Q4 2024 and Q1 2025 revenues reaching 8.494 billion CNY (YoY +20.71%) and 4.658 billion CNY (YoY +27.74%) respectively [6][8]. - The operating cash flow for 2024 was 2.495 billion CNY, a significant increase of 613.39% year-on-year, marking a historical high due to increased sales collections [6][11]. - The company’s R&D investment in 2024 was 4.58 billion CNY, a 19.37% increase from 2023, focusing on large model development and core technology autonomy [6][8]. Business Segments - The company adjusted its revenue structure in 2024, with significant growth in AI applications: smart education revenue was 7.229 billion CNY (YoY +29.94%), smart automotive revenue was 989 million CNY (YoY +42.16%), and enterprise AI solutions revenue was 643 million CNY (YoY +122.56%) [6][8]. - The company’s AI open platform generated 5.172 billion CNY in revenue (YoY +31.33%), while smart hardware revenue reached 2.023 billion CNY (YoY +25.07%) [6][8]. Financial Projections - The company’s projected net profits for 2025-2027 are 828 million CNY, 1.086 billion CNY, and 1.434 billion CNY respectively, with corresponding EPS of 0.36 CNY, 0.47 CNY, and 0.62 CNY [6][10]. - The P/E ratios for 2025-2027 are projected to be 126.1, 96.2, and 72.8 respectively, indicating a potential for growth in valuation [10][12].

Investment Rating - The report maintains a "Recommended" rating for the company [12] Core Views - The company achieved a revenue of 637 million yuan in 2024, representing a year-on-year growth of 25.14%, and a net profit of 293 million yuan, up 35.06% year-on-year [5] - The company is experiencing robust domestic growth while showing impressive performance overseas, with international revenue reaching 333 million yuan, a year-on-year increase of 36.19% [9] - The company has a strong focus on research and development, with R&D expenses increasing by 43.53% year-on-year to 59.21 million yuan in 2024 [11] Financial Performance Summary - Revenue projections for 2024 to 2027 are as follows: 637 million yuan (2024), 851 million yuan (2025), 1,065 million yuan (2026), and 1,333 million yuan (2027) [7] - Net profit projections for the same period are: 293 million yuan (2024), 328 million yuan (2025), 402 million yuan (2026), and 499 million yuan (2027) [7] - The company maintains a high gross margin of 72.1% in 2024, with a slight decrease expected in subsequent years [10] Market and Product Insights - The domestic market sales are projected to reach 300 million yuan in 2024, with a year-on-year growth of 14.63% [9] - The company has established partnerships with over 600 hospitals and has expanded its international client base to 116, marking a 23.4% increase [9] - The company’s GI product line is expected to generate 413 million yuan in revenue in 2024, reflecting a year-on-year growth of 23.17% [10] Valuation Metrics - The projected P/E ratio for 2024 is 18.1, decreasing to 10.7 by 2027, indicating an attractive valuation over time [16] - The projected P/B ratio for 2024 is 2.2, expected to decline to 1.6 by 2027 [16]